key: cord-0755197-91gzklkd authors: Baldi, Bruno Guedes; Radzikowska, Elzbieta; Cottin, Vincent; Dilling, Daniel F.; Ataya, Ali; Ribeiro Carvalho, Carlos Roberto; Harari, Sergio; Koslow, Matthew; Grutters, Jan C.; Inoue, Yoshikazu; Gupta, Nishant; Johnson, Simon R. title: COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition date: 2021-12-21 journal: Chest DOI: 10.1016/j.chest.2021.12.640 sha: 1089f27b916da1dec22e92b8e936336dcde963da doc_id: 755197 cord_uid: 91gzklkd nan Lymphangioleiomyomatosis (LAM) is a rare low-grade neoplastic lung disease that occurs sporadically in women or in people with tuberous sclerosis complex (TSC). Mechanistic target of rapamycin (mTOR) inhibitors are used for patients with progressive or severe pulmonary impairment or extrapulmonary manifestations. 1 Coronavirus disease 19 (COVID-19) is associated with worse outcomes in chronic pulmonary diseases, 2-4 however, only a small number of patients with LAM and COVID-19 have been reported and the outcomes and impact of mTOR inhibitors in LAM and COVID-19 infection are unclear. [5] [6] [7] We conducted an international study to evaluate the consequences of COVID-19 in patients with LAM and the impact of mTOR inhibitors on outcomes following COVID-19. We conducted a retrospective observational study that assessed patients with LAM The impact of mTOR inhibitors on COVID-19 outcomes is not well understood. While it is generally believed that patients with underlying immunosuppression are at increased risk of COVID-19 related complications, 2 there is speculation that mTOR inhibitors may have a beneficial impact in patients with COVID-19 owing to their in vitro inhibitory effects on viral replication and their potential to mitigate cytokine storm. 10 In a small series from Brazil, six patients with LAM had COVID-19, half were using sirolimus, and all completely recovered from the infection. 5 In our study, the use of mTOR inhibitors was not associated with worse outcomes, despite these patients having poorer lung function than untreated patients, which should provide reassurance to LAM patients and clinicians. Our study has several limitations. The number of patients with LAM who had COVID-19 may have been underestimated due to our criteria limiting inclusion to confirmed cases that excluded asymptomatic patients and patients who were not tested. Majority of the patients in our study contracted COVID-19 prior to the widespread availability of COVID-19 vaccines or the worldwide emergence of the delta variant, and the impact of these variables on outcomes following COVID-19 in patients with LAM remains unknown. Asthenia is frequently experienced by women with LAM and might have led to the overestimation of prevalence of long COVID in our study. Other limitations include the lack of a control group or propensity score matching and the non-standardized and evolving treatment paradigms for COVID-19 in different countries. Additionally, some of the results obtained may be explained by a type II error. These limitations, however, are mitigated by the inclusion of data from multiple international centers and the relatively large sample size for a rare disease. In conclusion, this multicenter study demonstrates that the risks of death and long COVID following COVID-19 in women with LAM are similar to the general population, and that mTOR inhibitors are not associated with worse outcomes. J o u r n a l P r e -p r o o f Diabetes (n, %) 6 (6.6%) Cancer (n, %) 3 (3.3%) Chronic kidney disease (n, %) 6 (6.6%) Heart failure, coronary artery disease or cardiomyopathy (n, %) * Partial information about six patients from Brazil was described in a previous report (reference 5). ** Two patients were enrolled in a double-blind placebo-controlled trial of sirolimus versus placebo, and, therefore, were not included in this analysis. *** Other symptoms include nausea, chest pain, night sweats, myalgia, sore throat, and dysphonia. **** The most common manifestation of long-COVID-19 was fatigue. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study Risk factors for mortality after COVID-19 in patients with preexisting interstitial lung disease Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study Online ahead of print COVID-19 and lymphangioleiomyomatosis: experience at a reference center and the potential impact of the use of mTOR inhibitors Tuberous sclerosis complex (TSC), lymphangioleiomyomatosis, and COVID-19: The experience of a TSC clinic in Italy Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: a novel intervention strategy beyond vaccines and specific antiviral medicines Coronavirus Disease 2019 case surveillance -United States Prevalence of long COVID symptoms and COVID-19 complications. Release date: 16 Abbreviations: BMI: body mass index; COVID-19: coronavirus disease 2019; DLCO: diffusing capacity of the lungs for carbon monoxide LAM: lymphangioleiomyomatosis; mTOR: mechanistic target of rapamycin * Two patients were enrolled in a double-blind placebo-controlled trial of sirolimus versus placebo, and, therefore, were not included in this analysis cancer, chronic kidney disease, heart failure, coronary artery disease or cardiomyopathy, and sickle cell disease We thank Drs Roberto Cassandro, Gregory Downey, Dominique Israel-Biet, Hirose Masaki, Francis McCormack, Hilario Nunes, and Yurdagül Uzunhan for contributing subjects in the study. BB, NG, and SJ conceived the study design and developed the data collection instrument. BB performed the data analysis. All listed authors contributed patient data to the study. BB, NG, and SJ wrote the initial draft of the manuscript that was subsequently edited and approved by all listed authors. BB, NG, and SJ had full access to all the data in this study, and had final responsibility for the decision to submit for publication.